Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS 2 | JAN 08 | CHEMLIST enhanced with New Zealand Inventory of Chemicals |
| NEWS 3 | JAN 16 | CA/CAplus Company Name Thesaurus enhanced and reloaded |
| NEWS 4 | JAN 16 | IPC version 2007.01 thesaurus available on STN |
| NEWS 5 | JAN 16 | WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data |
| NEWS 6 | JAN 22 | CA/CAplus updated with revised CAS roles |
| NEWS 7 | JAN 22 | CA/CAplus enhanced with patent applications from India |
| NEWS 8 | JAN 29 | PHAR reloaded with new search and display fields |
| NEWS 9 | JAN 29 | CAS Registry Number crossover limit increased to 300,000 in multiple databases |
| NEWS 10 | FEB 15 | PATDPASPC enhanced with Drug Approval numbers |
| NEWS 11 | FEB 15 | RUSSIAPAT enhanced with pre-1994 records |
| NEWS 12 | FEB 23 | KOREAPAT enhanced with IPC 8 features and functionality |
| NEWS 13 | FEB 26 | MEDLINE reloaded with enhancements |
| NEWS 14 | FEB 26 | EMBASE enhanced with Clinical Trial Number field |
| NEWS 15 | FEB 26 | TOXCENTER enhanced with reloaded MEDLINE |
| NEWS 16 | FEB 26 | IFICDB/IFIPAT/IFIUDB reloaded with enhancements |
| NEWS 17 | FEB 26 | CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases |
| NEWS 18 | MAR 15 | WPIDS/WPIX enhanced with new FRAGHITSTR display format |
| NEWS 19 | MAR 16 | CASREACT coverage extended |
| NEWS 20 | MAR 20 | MARPAT now updated daily |
| NEWS 21 | MAR 22 | LWPI reloaded |
| NEWS 22 | MAR 30 | RDISCLOSURE reloaded with enhancements |
| NEWS 23 | APR 02 | JICST-EPLUS removed from database clusters and STN |
| NEWS 24 | APR 30 | GENBANK reloaded and enhanced with Genome Project ID field |
| NEWS 25 | APR 30 | CHEMCATS enhanced with 1.2 million new records |
| NEWS 26 | APR 30 | CA/CAplus enhanced with 1870-1889 U.S. patent records |
| NEWS 27 | APR 30 | INPADOC replaced by INPADOCDB on STN |
| NEWS 28 | MAY 01 | New CAS web site launched |
| NEWS 29 | MAY 08 | CA/CAplus Indian patent publication number format defined |
| NEWS 30 | MAY 14 | RDISCLOSURE on STN Easy enhanced with new search and display fields |
| NEWS 31 | MAY 21 | BIOSIS reloaded and enhanced with archival data |
| NEWS 32 | MAY 21 | TOXCENTER enhanced with BIOSIS reload |
| NEWS 33 | MAY 21 | CA/CAplus enhanced with additional kind codes for German patents |
| NEWS 34 | MAY 22 | CA/CAplus enhanced with IPC reclassification in Japanese patents |

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:40:42 ON 25 MAY 2007

=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'CAPLUS' ENTERED AT 11:40:51 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 May 2007  VOL 146 ISS 23
FILE LAST UPDATED: 24 May 2007  (20070524/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> E US2005-523276/AP,PRN 25
E1            1     US2005-523271/AP
E2            1     US2005-523273/AP
E3            1 --> US2005-523276/AP
E4            0     US2005-523276/PRN
E5            1     US2005-523277/AP
E6            1     US2005-523278/AP
E7            1     US2005-523279/AP
E8            1     US2005-523281/AP
E9            1     US2005-523282/AP
E10           1     US2005-523284/AP
E11           1     US2005-523285/AP
E12           1     US2005-523286/AP
E13           1     US2005-523287/AP
```

```
E14           1     US2005-52329/AP
E15           1     US2005-52329/PRN
E16           1     US2005-523290/AP
E17           1     US2005-523291/AP
E18           1     US2005-523292/AP
E19           1     US2005-523295/AP
E20           1     US2005-523301/AP
E21           1     US2005-523302/AP
E22           1     US2005-523304/AP
E23           1     US2005-523306/AP
E24           1     US2005-523308/AP
E25           1     US2005-52331/AP

=> S E3
L1            1 US2005-523276/AP

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     2.95       3.16

FILE 'REGISTRY' ENTERED AT 11:42:15 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 MAY 2007  HIGHEST RN 935837-89-1
DICTIONARY FILE UPDATES:  24 MAY 2007  HIGHEST RN 935837-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> tra l1 1- /rn
L2            TRANSFER L1 1- TI :       6 TERMS
L3             0 L2/RN

=> tra l1 1- rn
L4            TRANSFER L1 1- RN :      23 TERMS
L5            23 L4

=> d scan
```

L5 23 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrole-3-propanoic acid, 5-(formyl-14C)-2,4-dimethyl- (9CI)
MF C10 H13 N O3



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> l5
L6          23 L4

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.45      28.30

FILE 'CAPLUS' ENTERED AT 11:43:55 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 May 2007  VOL 146 ISS 23
FILE LAST UPDATED: 24 May 2007  (20070524/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> l5
L7       18073 L5

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.47      28.77

FILE 'REGISTRY' ENTERED AT 11:44:36 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 MAY 2007  HIGHEST RN 935837-89-1
DICTIONARY FILE UPDATES:  24 MAY 2007  HIGHEST RN 935837-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.
```

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d l5

L5 ANSWER 1 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-89-3 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-carboxamide, 5-(formyl-14C)-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H23 N3 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l5 2

L5 ANSWER 2 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-88-2 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-propanoic acid, 2-(formyl-14C)-5-methyl- (9CI) (CA INDEX NAME)
MF C9 H11 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l5 3

L5 ANSWER 3 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-87-1 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-(formyl-14C)-2,4-dimethyl- (9CI) (CA INDEX NAME)
MF C14 H23 N3 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l5 4

L5 ANSWER 4 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-86-0 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-carboxylic acid, 5-(formyl-14C)-2,4-dimethyl- (9CI) (CA INDEX NAME)
MF C8 H9 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l5 5

L5 ANSWER 5 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-85-9 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-propanoic acid, 5-(formyl-14C)-2,4-dimethyl- (9CI) (CA INDEX NAME)
MF C10 H13 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l5 6-23

L5 ANSWER 6 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-84-8 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-2-carboxaldehyde-14C, 3,5-dimethyl- (9CI) (CA INDEX NAME)
MF C7 H9 N O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 7 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-83-7 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
MF C22 H27 F N4 O2
SR CA
LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 8 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-82-6 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
MF C18 H18 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 9 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-81-5 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H27 F N4 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 10 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-80-4 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-propanoic acid, 2-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-5-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H16 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 11 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-79-1 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H27 F N4 O2
SR CA
LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 12 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-78-0 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H18 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 13 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-77-9 REGISTRY
ED Entered STN: 01 Mar 2004
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene-14C]-1,3-dihydro- (9CI) (CA INDEX NAME)
MF C15 H14 N2 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 14 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 452105-36-1 REGISTRY
ED Entered STN: 17 Sep 2002
CN 4-Morpholineethanol, α-(aminomethyl)-, (αS)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (2S)-1-Amino-3-(morpholin-4-yl)propan-2-ol
FS STEREOSEARCH
MF C7 H16 N2 O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, CHEMCATS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 15 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 61853-17-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Formamide-14C, N,N-dimethyl- (6CI, 9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Formamide-14C, N,N-dimethyl- (7CI)
MF C3 H7 N O
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



12 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L5 ANSWER 16 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 60390-32-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Pyrrole-3-propanoic acid, 5-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Pyrrole-3-propionic acid, 5-methyl- (6CI)
MF C8 H11 N O2
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L5 ANSWER 17 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 56341-41-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro- (CA INDEX NAME)
OTHER NAMES:
CN 5-Fluoro-1,3-dihydro-2H-indol-2-one
CN 5-Fluoro-1,3-dihydroindol-2-one
CN 5-Fluoro-2,3-dihydro-2-oxoindole
CN 5-Fluoro-2-oxindole
CN 5-Fluoro-2-oxoindoline
CN 5-Fluorooxindole
MF C8 H6 F N O
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CSCHEM, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

86 REFERENCES IN FILE CA (1907 TO DATE)
86 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 18 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 54474-50-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Pyrrole-3-propanoic acid, 2,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Pyrrole-3-propionic acid, 2,4-dimethyl- (6CI, 7CI)
OTHER NAMES:
CN 3-(2,4-Dimethyl-1H-pyrrol-3-yl)propionic acid
MF C9 H13 N O2
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

21 REFERENCES IN FILE CA (1907 TO DATE)
21 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L5 ANSWER 19 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 2199-51-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Pyrrole-3-carboxylic acid, 2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Pyrrole-3-carboxylic acid, 2,4-dimethyl-, ethyl ester (6CI, 7CI, 8CI)
OTHER NAMES:
CN 2,4-Dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester
CN 2,4-Dimethyl-3-(ethoxycarbonyl)pyrrole
CN 2,4-Dimethyl-3-carbethoxypyrrole
CN 3-(Ethoxycarbonyl)-2,4-dimethylpyrrole
CN Ethyl 2,4-dimethylpyrrole-3-carboxylate
CN NSC 13425
MF C9 H13 N O2
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CSCHEM, IFICDB, IFIPAT, IFIUDB, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

106 REFERENCES IN FILE CA (1907 TO DATE)
106 REFERENCES IN FILE CAPLUS (1907 TO DATE)
22 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L5 ANSWER 20 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 625-82-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Pyrrole, 2,4-dimethyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Pyrrole, 2,4-dimethyl- (6CI, 7CI, 8CI)
OTHER NAMES:
CN 2,4-Dimethyl-1H-pyrrole
CN 2,4-Dimethylpyrrole
CN NSC 81347
MF C6 H9 N
CI COM
LC STN Files: ANABSTR, BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, DETHERM*, IFICDB, IFIPAT, IFIUDB, NAPRALERT, SCISEARCH, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

281 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
282 REFERENCES IN FILE CAPLUS (1907 TO DATE)
14 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L5 ANSWER 21 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 120-72-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Indole (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indole (8CI)
OTHER NAMES:
CN 1-Azaindene
CN 1-Benzazole
CN 2,3-Benzopyrrole
CN Benzo[b]pyrrole
CN Ketole
CN NSC 1964
MF C8 H7 N
CI COM, RPS
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

13380 REFERENCES IN FILE CA (1907 TO DATE)
2139 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
13429 REFERENCES IN FILE CAPLUS (1907 TO DATE)
6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L5 ANSWER 22 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 108-00-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1,2-Ethanediamine, N1,N1-dimethyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,2-Ethanediamine, N,N-dimethyl- (9CI)
CN Ethylenediamine, N,N-dimethyl- (6CI, 7CI, 8CI)
OTHER NAMES:
CN (2-Aminoethyl)dimethylamine
CN β-(Dimethylamino)ethylamine
CN 1-Amino-2-(dimethylamino)ethane
CN 2-(Dimethylamino)ethanamine
CN 2-(Dimethylamino)ethylamine
CN 2-(N,N-Dimethylamino)ethanamine
CN 2-(N,N-Dimethylamino)ethylamine
CN N,N-Dimethyl-1,2-diaminoethane
CN N,N-Dimethyl-1,2-ethanediamine
CN N,N-Dimethyl-1,2-ethylenediamine
CN N,N-Dimethylethanediamine
CN N,N-Dimethylethylenediamine
CN N,N-Methyl-1,2-ethanediamine
CN N-(2-Aminoethyl)-N,N-dimethylamine
CN NSC 24506
CN unsym-Dimethylethylenediamine
MF C4 H12 N2
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, GMELIN*, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

3376 REFERENCES IN FILE CA (1907 TO DATE)
235 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3383 REFERENCES IN FILE CAPLUS (1907 TO DATE)
27 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L5 ANSWER 23 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 59-48-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2H-Indol-2-one, 1,3-dihydro- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Indolinone (7CI, 8CI)
CN Oxindole (6CI)
OTHER NAMES:
CN 1,3-Dihydro-2H-indol-2-one
CN 1,3-Dihydroindol-2-one
CN 2-Indolone
CN 2-Oxindole
CN 2-Oxo-2,3-dihydroindole
CN 2-Oxoindole
CN 2-Oxoindoline
CN Indol-2(3H)-one
CN Indoline-2-one
CN NSC 274863
CN Oxindol
MF C8 H7 N O
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, EMBASE, IFICDB, IFIPAT, IFIUDB, MEDLINE, NAPRALERT, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1092 REFERENCES IN FILE CA (1907 TO DATE)
96 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1096 REFERENCES IN FILE CAPLUS (1907 TO DATE)
27 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> d l5 12 /ide
'' MUST END IN '/Q', '/A', '/L', '/S' OR '/B'
The saved name for a query (or structure or screen set) must end with
'/Q'.  The saved name for an answer set must end with '/A'.  The saved
name for an L# list must end with '/L'.  SDI request names must end
with '/S'.  To see a list of all saved query, answer set,, and L# list
names for this loginid, enter "DISPLAY SAVED" at an arrow
prompt (=>).  Enter "DISPLAY SAVED/S" to see a list of SDI request
names.  Enter "DISPLAY SAVED/B" to see a list of BATCH search
requests.

=> d l5 12 ide
```

L5 ANSWER 12 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-78-0 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H18 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l5 12 all

L5 ANSWER 12 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-78-0 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H18 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation)

Ring System Data

| Elemental Analysis | Elemental Sequence | Size of the Rings | Ring System Formula | Ring Identifier | RID Occurrence |
|---|---|---|---|---|---|
| EA | ES | SZ | RF | RID | Count |
| C4N | NC4 | 5 | C4N | 16.136.9 | 1 |
| C4N-C6 | NC4-C6 | 5-6 | C8N | 333.151.56 | 1 |

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

AN 140:163705 CA
TI Process for preparation of isotopically labeled indolinone derivatives
IN Giribone, Danilo; Pignatti, Alberto; Fontana, Erminia
PA Pharmacia Italia S.P.A., Italy
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K051-04
ICS C07D403-06; C07D403-14; C07D471-04
CC 27-11 (Heterocyclic Compounds (One Hetero Atom))
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2004012776 | A1 | 20040212 | WO 2003-EP50340 | 20030728 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, | | | | |

L5 ANSWER 12 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN (Continued)
IT 120-72-9DP, Indole, isotopically labeled derivs. 656253-77-9P 656253-78-0P 656253-79-1P 656253-80-4P 656253-81-5P 656253-82-6P 656253-83-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of isotopically labeled indolinone derivs.)

L5 ANSWER 12 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN (Continued)
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003262544 A1 20040223 AU 2003-262544 20030728
EP 1542734 A1 20050622 EP 2003-766410 20030728
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006515564 T 20060601 JP 2004-525429 20030728
US 2006166982 A1 20060727 US 2005-523276 20050919
PRAI EP 2002-78164 20020801
WO 2003-EP50340 20030728
GI



I



II

AB This invention pertains to a method for producing isotopically labeled [14C] indolinone derivs. with general formula of I [wherein R = alkyl, alkoxy, or halo; R1 = (un)substituted alkyl or CONH2; m = 0-4; n = 0-3] or pharmaceutically acceptable salts. For example, H14CONMe2 was reacted with 2,4-dimethylpyrrole in diphosphoryl chloride to give 3,5-dimethyl-1H-pyrrole-2-[14C]carboxaldehyde (49%). The above aldehyde was reacted with oxindole in EtOH in the presence of pyrrolidine to afford II (54%).
ST isotopically labeling pyrrolyl indolinone prepn
IT Exchange reaction
(preparation of isotopically labeled indolinone derivs.)
IT 656253-84-8P 656253-85-9P 656253-86-0P 656253-87-1P 656253-88-2P 656253-89-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of isotopically labeled indolinone derivs.)
IT 59-48-3, Oxindole 108-00-9, N,N-Dimethylethane-1,2-diamine 625-82-1, 2,4-Dimethylpyrrole 2199-51-1, 2,4-Dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester 54474-50-9 56341-41-4 60390-32-1 61853-17-6 452105-36-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of isotopically labeled indolinone derivs.)

```
=> l5 Nc4-C6/ES
MISSING OPERATOR

=> l5 and Nc4-C6/ES
      1115147 NC4-C6/ES
L8          10 L5 AND NC4-C6/ES

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    59.82      88.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -0.73      -0.73

FILE 'CAPLUS' ENTERED AT 11:48:11 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 May 2007  VOL 146 ISS 23
FILE LAST UPDATED: 24 May 2007  (20070524/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> l8
L9       14388 L8

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.47      89.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -0.73

FILE 'CAPLUS' ENTERED AT 11:48:20 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 25 May 2007 VOL 146 ISS 23
FILE LAST UPDATED: 24 May 2007 (20070524/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> l8
L10 14388 L8

=> l5 and Nc4-C6/ES
'ES' IS NOT A VALID FIELD CODE
18073 L5
0 NC4-C6/ES
L11 0 L5 AND NC4-C6/ES

=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.47 | 89.53 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | 0.00 | -0.73 |

FILE 'REGISTRY' ENTERED AT 11:48:38 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1
DICTIONARY FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of

experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> l5 and Nc4-C6/ES
       1115147 NC4-C6/ES
L12          10 L5 AND NC4-C6/ES

=> d 1-10
```

L12 ANSWER 1 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-83-7 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
MF C22 H27 F N4 O2
SR CA
LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 2 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-82-6 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
MF C18 H18 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 3 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-81-5 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H27 F N4 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 4 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-80-4 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-propanoic acid, 2-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-5-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H16 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-79-1 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H27 F N4 O2
SR CA
LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 6 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-78-0 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H18 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 7 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-77-9 REGISTRY
ED Entered STN: 01 Mar 2004
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene-14C]-1,3-dihydro- (9CI) (CA INDEX NAME)
MF C15 H14 N2 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
RN 56341-41-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro- (CA INDEX NAME)
OTHER NAMES:
CN 5-Fluoro-1,3-dihydro-2H-indol-2-one
CN 5-Fluoro-1,3-dihydroindol-2-one
CN 5-Fluoro-2,3-dihydro-2-oxoindole
CN 5-Fluoro-2-oxindole
CN 5-Fluoro-2-oxoindoline
CN 5-Fluorooxindole
MF C8 H6 F N O
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CSCHEM, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

86 REFERENCES IN FILE CA (1907 TO DATE)
86 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 9 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
RN 120-72-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Indole (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indole (8CI)
OTHER NAMES:
CN 1-Azaindene
CN 1-Benzazole
CN 2,3-Benzopyrrole
CN Benzo[b]pyrrole
CN Ketole
CN NSC 1964
MF C8 H7 N
CI COM, RPS
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

13380 REFERENCES IN FILE CA (1907 TO DATE)
2139 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
13429 REFERENCES IN FILE CAPLUS (1907 TO DATE)
6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L12 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
RN 59-48-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2H-Indol-2-one, 1,3-dihydro- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Indolinone (7CI, 8CI)
CN Oxindole (6CI)
OTHER NAMES:
CN 1,3-Dihydro-2H-indol-2-one
CN 1,3-Dihydroindol-2-one
CN 2-Indolone
CN 2-Oxindole
CN 2-Oxo-2,3-dihydroindole
CN 2-Oxoindole
CN 2-Oxoindoline
CN Indol-2(3H)-one
CN Indoline-2-one
CN NSC 274863
CN Oxindol
MF C8 H7 N O
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, EMBASE, IFICDB, IFIPAT, IFIUDB, MEDLINE, NAPRALERT, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1092 REFERENCES IN FILE CA (1907 TO DATE)
96 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1096 REFERENCES IN FILE CAPLUS (1907 TO DATE)
27 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> l5 and Nc4-C6/ES and NC4/es
       1115147 NC4-C6/ES
       1664117 NC4/ES
L13           7 L5 AND NC4-C6/ES AND NC4/ES

=> d 1-7
```

L13 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-83-7 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
MF C22 H27 F N4 O2
SR CA
LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-82-6 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
MF C18 H18 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-81-5 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H27 F N4 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-80-4 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-propanoic acid, 2-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-5-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H16 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-79-1 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H27 F N4 O2
SR CA
LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-78-0 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H18 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-77-9 REGISTRY
ED Entered STN: 01 Mar 2004
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene-14C]-1,3-dihydro- (9CI) (CA INDEX NAME)
MF C15 H14 N2 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 48.90 | 138.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION
CA SUBSCRIBER PRICE | 0.00 | -0.73

FILE 'CAPLUS' ENTERED AT 11:49:39 ON 25 MAY 2007


FILE COVERS 1907 - 25 May 2007 VOL 146 ISS 23
FILE LAST UPDATED: 24 May 2007 (20070524/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> l13
L14 1 L13

=> d ibib abs hitstr

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:120755 CAPLUS
DOCUMENT NUMBER: 140:163705
TITLE: Process for preparation of isotopically labeled indolinone derivatives
INVENTOR(S): Giribone, Danilo; Pignatti, Alberto; Fontana, Erminia
PATENT ASSIGNEE(S): Pharmacia Italia S.P.A., Italy
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004012776 | A1 | 20040212 | WO 2003-EP50340 | 20030728 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003262544 | A1 | 20040223 | AU 2003-262544 | 20030728 |
| EP 1542734 | A1 | 20050622 | EP 2003-766410 | 20030728 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| JP 2006515564 | T | 20060601 | JP 2004-525429 | 20030728 |
| US 2006166982 | A1 | 20060727 | US 2005-523276 | 20050919 |
| PRIORITY APPLN. INFO.: | | | EP 2002-78164 A | 20020801 |
| | | | WO 2003-EP50340 W | 20030728 |

OTHER SOURCE(S): MARPAT 140:163705
GI


I


II

AB This invention pertains to a method for producing isotopically labeled [14C] indolinone derivs. with general formula of I [wherein R = alkyl, alkoxy, or halo; R1 = (un)substituted alkyl or CONH2; m = 0-4; n = 0-3] or pharmaceutically acceptable salts. For example, H14CONMe2 was reacted with 2,4-dimethylpyrrole in diphosphoryl chloride to give 3,5-dimethyl-1H-pyrrole-2-[14C]carboxaldehyde (49%). The above aldehyde was reacted with oxindole in EtOH in the presence of pyrrolidine to afford II (54%).

IT 656253-77-9P 656253-78-0P 656253-79-1P 656253-80-4P 656253-81-5P 656253-82-6P 656253-83-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of isotopically labeled indolinone derivs.)

RN 656253-77-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene-14C]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 656253-78-0 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 656253-79-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 656253-80-4 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 656253-81-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 656253-82-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 656253-83-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)



=> file reg
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 8.09 | 146.52

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION
CA SUBSCRIBER PRICE | -0.78 | -1.51

FILE 'REGISTRY' ENTERED AT 11:53:19 ON 25 MAY 2007


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1
DICTIONARY FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10523276\Struc 1.str





chain nodes :
1 4 5 6
ring nodes :
2 3 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-9 4-17 5-15 5-7 6-16
ring bonds :
2-9 2-10 3-15 3-17 7-8 7-9 8-10 8-11 10-12 11-13 12-14 13-14 15-16 16-18 17-18
exact/norm bonds :
1-9 2-9 2-10 3-15 3-17 7-8 7-9 15-16 16-18 17-18
exact bonds :
4-17 5-15 5-7 6-16
normalized bonds :

8-10 8-11 10-12 11-13 12-14 13-14

Match level :
1:CLASS 2:Atom 3:Atom 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L15 STRUCTURE UPLOADED

=> d
L15 HAS NO ANSWERS
L15 STR




Structure attributes must be viewed using STN Express query preparation.

=> l15
SAMPLE SEARCH INITIATED 11:53:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 221 TO ITERATE

100.0% PROCESSED 221 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3529 TO 5311
PROJECTED ANSWERS: 1081 TO 2159

L16 50 SEA SSS SAM L15

=> l15 exa
SAMPLE SEARCH INITIATED 11:53:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L17 0 SEA EXA SAM L15

```
=> d scan
L17 HAS NO ANSWERS


=> d scan l16
```

L16 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Heptanoic acid, 7-[[[5-[(Z)-(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3,5-dihydroxy-, (3R,5R)-
MF C23 H25 F2 N3 O6
CI COM

Absolute stereochemistry.
Double bond geometry as shown.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L16 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrole-2-carboxylic acid, 1-[4-[[[5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3-methoxy-1-oxobutyl]-2,5-dihydro-
MF C26 H27 F N4 O6

Double bond geometry as shown.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L16 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrole-3-propanamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N,2,4-trimethyl-N-[7-(methylamino)heptyl]- (9CI)
MF C27 H38 N4 O2
CI COM



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L16 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN L-Threonine, N-[2-ethoxy-4-[[[5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-1-oxobutyl]-
MF C26 H31 F N4 O7

Absolute stereochemistry.
Double bond geometry as shown.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L16 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2H-Indol-2-one, 3-[[4-[(cyclopropylmethylamino)methyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-[[[2-[2-(4-morpholinyl)ethoxy]phenyl]methyl]sulfonyl]-, (3Z)- (9CI)
MF C33 H40 N4 O5 S

Double bond geometry as shown.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> file guide
'GUIDE' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'REGISTRY'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file stnguide
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     2.25     148.77

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.51

FILE 'STNGUIDE' ENTERED AT 11:56:33 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 18, 2007 (20070518/UP).

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.24     149.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.51

FILE 'REGISTRY' ENTERED AT 11:58:44 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 MAY 2007  HIGHEST RN 935837-89-1
DICTIONARY FILE UPDATES:  24 MAY 2007  HIGHEST RN 935837-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:
```

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10523276\Struc 7.str



chain nodes :
1 4 5 6 7 8 9 10 11 12 13 14
ring nodes :
2 3 15 16 17 18 19 20 21 22 23 24 25 26
chain bonds :
1-17 4-26 5-23 5-15 6-21 7-24 8-25 8-9 8-14 9-10 10-11 11-12 12-13
ring bonds :
2-17 2-18 3-23 3-26 15-16 15-17 16-18 16-19 18-20 19-21 20-22 21-22
23-24 24-25 25-26
exact/norm bonds :
1-17 2-17 2-18 3-23 3-26 8-9 8-14 15-16 15-17 23-24 24-25 25-26
exact bonds :
4-26 5-23 5-15 6-21 7-24 8-25 9-10 10-11 11-12 12-13
normalized bonds :
16-18 16-19 18-20 19-21 20-22 21-22

Match level :
1:CLASS 2:Atom 3:Atom 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom
18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom

L18 STRUCTURE UPLOADED

=>
Uploading c:\Program Files\Stnexp\Queries\10523276\Struc 2.str



chain nodes :
1 3 4 5 6 8 21 22
ring nodes :
2 7 9 10 11 12 13 14 15 16 17 18 19 20
chain bonds :
1-18 3-11 4-22 5-20 6-17 6-8 6-9 19-21 21-22
ring bonds :

2-11 2-12 7-17 7-20 9-10 9-11 10-12 10-13 12-14 13-15 14-16 15-16 17-18
18-19 19-20
exact/norm bonds :
2-11 2-12 3-11 7-17 7-20 9-10 9-11 17-18 18-19 19-20
exact bonds :
1-18 4-22 5-20 6-17 6-8 6-9 19-21 21-22
normalized bonds :
10-12 10-13 12-14 13-15 14-16 15-16

Match level :
1:CLASS 2:Atom 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:CLASS 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom
19:Atom 20:Atom 21:CLASS 22:CLASS

L19 STRUCTURE UPLOADED

=>
Uploading c:\Program Files\Stnexp\Queries\10523276\Struc 3.str



chain nodes :
1 2 4 5 6 7 8 9 10 12 25 26 27
ring nodes :
3 11 13 14 15 16 17 18 19 20 21 22 23 24
chain bonds :
1-25 2-22 4-15 5-6 5-27 7-25 7-26 8-24 9-19 10-21 10-12 10-13 23-25
26-27
ring bonds :
3-15 3-16 11-21 11-24 13-14 13-15 14-16 14-17 16-18 17-19 18-20 19-20
21-22 22-23 23-24
exact/norm bonds :
1-25 3-15 3-16 4-15 5-27 7-25 7-26 11-21 11-24 13-14 13-15 21-22 22-23
23-24
exact bonds :
2-22 5-6 8-24 9-19 10-21 10-12 10-13 23-25 26-27
normalized bonds :
14-16 14-17 16-18 17-19 18-20 19-20

Match level :
1:CLASS 2:CLASS 3:Atom 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom
19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS 26:CLASS 27:CLASS

L20 STRUCTURE UPLOADED

=>
Uploading c:\Program Files\Stnexp\Queries\10523276\Struc 4.str



chain nodes :
1 3 4 5 7 20 21
ring nodes :
2 6 8 9 10 11 12 13 14 15 16 17 18 19
chain bonds :
1-21 3-10 4-19 5-16 5-7 5-8 17-20 20-21
ring bonds :
2-10 2-11 6-16 6-19 8-9 8-10 9-11 9-12 11-13 12-14 13-15 14-15 16-17
17-18 18-19
exact/norm bonds :
2-10 2-11 3-10 6-16 6-19 8-9 8-10 16-17 17-18 18-19
exact bonds :
1-21 4-19 5-16 5-7 5-8 17-20 20-21
normalized bonds :
9-11 9-12 11-13 12-14 13-15 14-15

Match level :
1:CLASS 2:Atom 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:CLASS 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom
19:Atom 20:CLASS 21:CLASS

L21 STRUCTURE UPLOADED

=>
Uploading c:\Program Files\Stnexp\Queries\10523276\Struc 5.str



chain nodes :

1 2 4 5 7 9 10 11 13 26 27 28 29
ring nodes :
3 6 8 12 14 15 16 17 18 19 20 21 22 23 24 25 30 31 32 33
chain bonds :
1-26 2-23 4-16 5-26 5-27 6-29 7-28 9-25 10-20 11-22 11-13 11-14 24-26
27-28 28-29
ring bonds :
3-16 3-17 6-30 6-31 8-32 8-33 12-22 12-25 14-15 14-16 15-17 15-18 17-19
18-20 19-21 20-21 22-23 23-24 24-25 30-32 31-33
exact/norm bonds :
1-26 3-16 3-17 4-16 5-26 5-27 6-29 6-30 6-31 7-28 8-32 8-33 12-22
12-25 14-15 14-16 22-23 23-24 24-25 30-32 31-33
exact bonds :
2-23 9-25 10-20 11-22 11-13 11-14 24-26 27-28 28-29
normalized bonds :
15-17 15-18 17-19 18-20 19-21 20-21

Match level :
1:CLASS 2:CLASS 3:Atom 4:CLASS 5:CLASS 6:Atom 7:CLASS 8:Atom 9:CLASS
10:CLASS 11:CLASS 12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom
19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:Atom 31:Atom 32:Atom 33:Atom

Stereo Bonds:

28-7 (Single Wedge).

Stereo Chiral Centers:

28 (Parity=Don't Care)

Stereo RSS Sets:

Type=Relative (Default). 1 Nodes= 28

L22 STRUCTURE UPLOADED

=>
Uploading c:\Program Files\Stnexp\Queries\10523276\Struc 6.str



chain nodes :
1 4 5 6 7 8 9
ring nodes :
2 3 10 11 12 13 14 15 16 17 18 19 20 21
chain bonds :
1-12 4-21 5-18 5-10 6-19 7-20 7-8 8-9
ring bonds :
2-12 2-13 3-18 3-21 10-11 10-12 11-13 11-14 13-15 14-16 15-17 16-17
18-19 19-20 20-21

```
exact/norm bonds :
1-12  2-12  2-13  3-18  3-21  10-11  10-12  18-19  19-20  20-21
exact bonds :
4-21  5-18  5-10  6-19  7-20  7-8  8-9
normalized bonds :
11-13  11-14  13-15  14-16  15-17  16-17


Match level :
1:CLASS  2:Atom  3:Atom  4:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:CLASS
10:Atom  11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom
19:Atom  20:Atom  21:Atom



L23     STRUCTURE UPLOADED

=> l18 exa
SAMPLE SEARCH INITIATED 11:59:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L24           0 SEA EXA SAM L18

=> l19 exa
SAMPLE SEARCH INITIATED 11:59:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L25           0 SEA EXA SAM L19

=> l20 exa
SAMPLE SEARCH INITIATED 12:00:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0
```

```
L26           0 SEA EXA SAM L20

=> l21 exa
SAMPLE SEARCH INITIATED 12:00:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L27           0 SEA EXA SAM L21

=> l22 exa
SAMPLE SEARCH INITIATED 12:00:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        1 TO ITERATE

100.0% PROCESSED        1 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            1 TO       80
PROJECTED ANSWERS:               0 TO        0

L28           0 SEA EXA SAM L22

=> l23 exa
SAMPLE SEARCH INITIATED 12:00:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L29           0 SEA EXA SAM L23

=> d his

     (FILE 'HOME' ENTERED AT 11:40:42 ON 25 MAY 2007)

     FILE 'CAPLUS' ENTERED AT 11:40:51 ON 25 MAY 2007
               E US2005-523276/AP,PRN 25
L1            1 S E3

     FILE 'REGISTRY' ENTERED AT 11:42:15 ON 25 MAY 2007

     FILE 'CAPLUS' ENTERED AT 11:42:23 ON 25 MAY 2007
L2              TRA L1 1- TI :        6 TERMS
```

```
     FILE 'REGISTRY' ENTERED AT 11:42:24 ON 25 MAY 2007
L3            0 SEA L2/RN

     FILE 'CAPLUS' ENTERED AT 11:43:38 ON 25 MAY 2007
L4                TRA L1 1- RN :       23 TERMS

     FILE 'REGISTRY' ENTERED AT 11:43:38 ON 25 MAY 2007
L5           23 SEA L4
L6           23 L5

     FILE 'CAPLUS' ENTERED AT 11:43:55 ON 25 MAY 2007
L7        18073 L5

     FILE 'REGISTRY' ENTERED AT 11:44:36 ON 25 MAY 2007
L8           10 L5 AND NC4-C6/ES

     FILE 'CAPLUS' ENTERED AT 11:48:11 ON 25 MAY 2007
L9        14388 L8

     FILE 'CAPLUS' ENTERED AT 11:48:20 ON 25 MAY 2007
L10       14388 L8
L11           0 L5 AND NC4-C6/ES

     FILE 'REGISTRY' ENTERED AT 11:48:38 ON 25 MAY 2007
L12          10 L5 AND NC4-C6/ES
L13           7 L5 AND NC4-C6/ES AND NC4/ES

     FILE 'CAPLUS' ENTERED AT 11:49:39 ON 25 MAY 2007
L14           1 L13

     FILE 'REGISTRY' ENTERED AT 11:53:19 ON 25 MAY 2007
L15              STRUCTURE UPLOADED
L16          50 L15
L17           0 L15 EXA

     FILE 'STNGUIDE' ENTERED AT 11:56:33 ON 25 MAY 2007

     FILE 'REGISTRY' ENTERED AT 11:58:44 ON 25 MAY 2007
L18              STRUCTURE UPLOADED
L19              STRUCTURE UPLOADED
L20              STRUCTURE UPLOADED
L21              STRUCTURE UPLOADED
L22              STRUCTURE UPLOADED
L23              STRUCTURE UPLOADED
L24           0 L18 EXA
L25           0 L19 EXA
L26           0 L20 EXA
L27           0 L21 EXA
L28           0 L22 EXA
L29           0 L23 EXA

=> d l15
L15 HAS NO ANSWERS
L15              STR
```




Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\10523276\Struc 8.str





chain nodes :
1 4
ring nodes :
2 3 5 6 7 8 9 10 11 12 13 14 15 16
chain bonds :
1-7 4-13 4-5
ring bonds :
2-7 2-8 3-13 3-15 5-6 5-7 6-8 6-9 8-10 9-11 10-12 11-12 13-14 14-16
15-16
exact/norm bonds :
1-7 2-7 2-8 3-13 3-15 5-6 5-7 13-14 14-16 15-16
exact bonds :
4-13 4-5
normalized bonds :
6-8 6-9 8-10 9-11 10-12 11-12

Match level :
1:CLASS 2:Atom 3:Atom 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom

L30 STRUCTURE UPLOADED

=> d
L30 HAS NO ANSWERS
L30 STR




Structure attributes must be viewed using STN Express query preparation.

```
=> l30
SAMPLE SEARCH INITIATED 12:02:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      605 TO ITERATE

100.0% PROCESSED      605 ITERATIONS                                50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        10625 TO    13575
PROJECTED ANSWERS:            2654 TO     4226

L31          50 SEA SSS SAM L30

=> l30 full
FULL SEARCH INITIATED 12:02:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    12244 TO ITERATE

100.0% PROCESSED    12244 ITERATIONS                            3608 ANSWERS
SEARCH TIME: 00.00.01

L32        3608 SEA SSS FUL L30

=> file medline caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   174.80     323.81

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.51

FILE 'MEDLINE' ENTERED AT 12:02:45 ON 25 MAY 2007

FILE 'CAPLUS' ENTERED AT 12:02:45 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> l32
L33        760 L32

=> dup rem l32
DUPLICATE IS NOT AVAILABLE IN 'REGISTRY'.
```

```
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                73.02     396.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                 0.00      -1.51

FILE 'REGISTRY' ENTERED AT 12:02:54 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 MAY 2007  HIGHEST RN 935837-89-1
DICTIONARY FILE UPDATES:  24 MAY 2007  HIGHEST RN 935837-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html
PROCESSING COMPLETED FOR L32
L34         3608 DUP REM L32 (0 DUPLICATES REMOVED)
```

```
=> file medline caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.45     397.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.51

FILE 'MEDLINE' ENTERED AT 12:03:14 ON 25 MAY 2007

FILE 'CAPLUS' ENTERED AT 12:03:14 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> dup rem l33
PROCESSING COMPLETED FOR L33
L35          723 DUP REM L33 (37 DUPLICATES REMOVED)

=> d ibib abs hitstr 701-723
```

L35 ANSWER 701 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:810602 CAPLUS
DOCUMENT NUMBER: 132:160709
TITLE: Antiangiogenic agents
AUTHOR(S): Klohs, Wayne D.; Hamby, James M.
CORPORATE SOURCE: Department of Drug Development, Parke-Davis Pharmaceutical Research, Warner-Lambert Company, Ann Arbor, MI, 48105, USA
SOURCE: Current Opinion in Biotechnology (1999), 10(6), 544-549
CODEN: CUOBE3; ISSN: 0958-1669
PUBLISHER: Current Biology Publications
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 32 refs. A greater understanding of the complex process of tumor-induced angiogenesis, coupled with the notion that tumors require a blood supply to both grow and metastasize, has fueled the search for agents that block or disrupt the angiogenic process. Because normal vascular endothelial cells (ECs) turn over so slowly, conventional wisdom suggests that an antiangiogenic approach to cancer therapy should offer improved efficacy and reduced toxicity, without the potential for drug resistance. Numerous report have identified small mols. or antibodies that can interfere with one or more key steps in EC signaling, migration or differentiation. Three new compds., ZD4190, SU6668 and PD 0173074, have been reported during the past year to have significant and selective antiangiogenic activity, as well as antitumor activity.
IT 252916-29-3, SU6668
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiangiogenic agents for treatment of cancer)
RN 252916-29-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 702 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:728476 CAPLUS
DOCUMENT NUMBER: 132:58536
TITLE: Identification of geometric isomer of compound 3-(3,5-dimethyl-2-pyrrolylmethylene)-5-bromoindolone by using theoretical calculation and 1H NMR
AUTHOR(S): Zheng, Zhibing; Hu, Yuandong; Cui, Guangyao; Xie, Yunde; Jiao, Kefang; Li, Song
CORPORATE SOURCE: Inst. Pharmacol. Toxicol., Acad. Mil. Med. Sci., Beijing, 100850, Peop. Rep. China
SOURCE: Bopuxue Zazhi (1999), 16(5), 455-460
CODEN: BOZAE2; ISSN: 1000-4556
PUBLISHER: Zhongguo Kexueyuan Wuhan Wuli Yanjiuso
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
AB The methods of MM2 and AM1 of MOPAC97 was used to calculate the mol. geometric isomers. The distance parameters of the atoms of the two configurations of the mol. were calculated, and the possible NOE effects were predicted according to the necessary condition of having NOE between atoms. The geometric configuration of the mol. was confirmed by contrasting the results of exptl. and predicted NOE effects.
IT 194413-57-5 194413-58-6
RL: ANT (Analyte); PRP (Properties); ANST (Analytical study)
(identification of geometric isomer of compound 3-(3,5-dimethyl-2-pyrrolylmethylene)-5-bromoindolone by using theor. calcn. and 1H NMR)
RN 194413-57-5 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 194413-58-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L35 ANSWER 702 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L35 ANSWER 703 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:65738 CAPLUS
DOCUMENT NUMBER: 130:246450
TITLE: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
AUTHOR(S): Fong, T. Annie T.; Shawver, Laura K.; Sun, Li; Tang, Cho; App, Harald; Powell, T. Jeff; Kim, Young H.; Schreck, Randall; Wang, Xueyan; Risau, Werner; Ullrich, Axel; Hirth, K. Peter; McMahon, Gerald
CORPORATE SOURCE: SUGEN, Inc., South San Francisco, CA, 94080, USA
SOURCE: Cancer Research (1999), 59(1), 99-106
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: AACR Subscription Office
DOCUMENT TYPE: Journal
LANGUAGE: English
AB SU5416, a novel synthetic compound, is a potent and selective inhibitor of the Flk-1/KDR receptor tyrosine kinase that is presently under evaluation in Phase I clin. studies for the treatment of human cancers. SU5416 was shown to inhibit vascular endothelial growth factor-dependent mitogenesis of human endothelial cells without inhibiting the growth of a variety of tumor cells in vitro. In contrast, systemic administration of SU5416 at nontoxic doses in mice resulted in inhibition of s.c. tumor growth of cells derived from various tissue origins. The antitumor effect of SU5416 was accompanied by the appearance of pale white tumors that were resected from drug-treated animals, supporting the antiangiogenic property of this agent. These findings support that pharmacol. inhibition of the enzymic activity of the vascular endothelial growth factor receptor represents a novel strategy for limiting the growth of a wide variety of tumor types.
IT 204005-46-9, SU 5416
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SU5416: selective inhibitor of Flk-1/KDR receptor tyrosine kinase, tumor vascularization and growth)
RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 703 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L35 ANSWER 704 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:117816 CAPLUS
DOCUMENT NUMBER: 133:37825
TITLE: Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multifluorescence videomicroscopy
AUTHOR(S): Vajkoczy, Peter; Menger, Michael D.; Vollmar, Brigitte; Schilling, Lothar; Schmiedek, Peter; Hirth, K. Peter; Ullrich, Axel; Fong, T. Annie T.
CORPORATE SOURCE: Department of Neurosurgery, Klinikum Mannheim, University of Heidelberg, Mannheim, D-68167, Germany
SOURCE: Neoplasia (New York) (1999), 1(1), 31-41
CODEN: NEOPFL; ISSN: 1522-8002
PUBLISHER: Stockton Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Vascular endothelial growth factor (VEGF) plays a fundamental role in mediating tumor angiogenesis and tumor growth. The direct effect of SU5416, a novel small-mol. inhibitor of the Flk-1-mediated signal transduction pathway of VEGF, on tumor angiogenesis and microhemodynamics of an exptl. glioblastoma was investigated by intravital multifluorescence videomicroscopy. SU5416 treatment suppressed tumor growth. In parallel, SU5416 demonstrated a potent antiangiogenic activity, resulting in reduction of both the total and functional vascular d. of the tumor microvasculature, which indicates an impaired vascularization as well as perfusion failure in the treated tumors. This malperfusion was not compensated for by changes in vessel diameter or recruitment of nonperfused vessels. Analyses of the tumor microcirculation revealed microhemodynamic changes after angiogenesis blockade, such as a higher red cell velocity and blood flow in remnant tumor vessels than in controls. The results demonstrate that the novel antiangiogenic concept of targeting the tyrosine kinase of Flk-1/KDR by means of a small-mol. inhibitor represents an efficient strategy for controlling growth and progression of angiogenesis-dependent tumors.

IT 204005-46-9, SU 5416
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(inhibition of glioblastoma growth, angiogenesis, and microcirculation by tyrosine kinase inhibitor SU5416)

RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)

L35 ANSWER 704 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:747592 CAPLUS
DOCUMENT NUMBER: 130:3771
TITLE: Preparation of 3-(hetero)arylmethylidene-2-indolinone derivatives as modulators of protein kinase activity for use in treating cancer.
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Shawver, Laura Kay; Hirth, Klaus Peter
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 269 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9850356 | A1 | 19981112 | WO 1998-US9017 | 19980507 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| CA 2289102 | A1 | 19981112 | CA 1998-2289102 | 19980507 |
| AU 9876842 | A | 19981127 | AU 1998-76842 | 19980507 |
| EP 984930 | A1 | 20000315 | EP 1998-924746 | 19980507 |
| EP 984930 | B1 | 20050406 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2002511852 | T | 20020416 | JP 1998-548319 | 19980507 |
| AT 292623 | T | 20050415 | AT 1998-924746 | 19980507 |
| ES 2239393 | T3 | 20050916 | ES 1998-924746 | 19980507 |
| US 6051593 | A | 20000418 | US 1998-99721 | 19980619 |
| US 6313158 | B1 | 20011106 | US 1998-100854 | 19980619 |
| US 6133305 | A | 20001017 | US 1998-161046 | 19980925 |
| US 2001056094 | A1 | 20011227 | US 2000-482198 | 20000112 |
| US 2001007033 | A1 | 20010705 | US 2000-516948 | 20000301 |
| US 2002026053 | A1 | 20020228 | US 2001-916331 | 20010730 |
| US 6506763 | B2 | 20030114 | | |
| US 2002058661 | A1 | 20020516 | US 2001-948106 | 20010907 |
| US 6696463 | B2 | 20040224 | | |
| US 2002183370 | A1 | 20021205 | US 2001-29946 | 20011231 |
| US 6579897 | B2 | 20030617 | | |
| US 2004106630 | A1 | 20040603 | US 2003-725079 | 20031202 |
| US 2004106618 | A1 | 20040603 | US 2003-725267 | 20031202 |
| US 7189721 | B2 | 20070313 | | |

| PRIORITY APPLN. INFO.: | | |
|---|---|---|
| US 1997-45838P | P | 19970507 |
| US 1997-46868P | P | 19970508 |
| US 1997-49324P | P | 19970611 |
| US 1997-50412P | P | 19970620 |
| US 1997-50413P | P | 19970620 |

L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

| | | |
|---|---|---|
| US 1997-50977P | P | 19970620 |
| US 1997-59336P | P | 19970919 |
| US 1997-59381P | P | 19970919 |
| US 1997-59384P | P | 19970919 |
| US 1997-59544P | P | 19970919 |
| US 1997-59677P | P | 19970919 |
| US 1997-59971P | P | 19970925 |
| US 1997-60194P | P | 19970926 |
| US 1998-74621 | A3 | 19980507 |
| WO 1998-US9017 | W | 19980507 |
| US 1998-100854 | A3 | 19980619 |
| US 1998-99721 | A1 | 19980619 |
| US 1998-161046 | A3 | 19980925 |
| US 2000-482198 | A3 | 20000112 |
| US 2000-516948 | B1 | 20000301 |
| US 2001-819698 | A3 | 20010329 |

OTHER SOURCE(S): MARPAT 130:3771
GI



I

AB Title compds. [I; A1-A4 = C, N; when any of A1-A4 = N, then the corresponding R3-R6 = null; R1 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclyl, trihalomethylcarbonyl, OH, CO2H, trihalomethylsulfonyl, etc.; R2 = H, alkyl, cycloalkyl, aryl, heteroaryl,

L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

heteroalicyclyl, halo; R3-R6 = H, alkyl, trihalomethyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclyl, OH, SH, alkoxy, aryloxy, amino, phosphonyl, guanidinyl, NO2, halo, (iso)cyanato, etc.; R3R4 or R4R5 or R5R6 = cycloalkyl, aryl, heteroaryl, heteroalicyclyl, OCH2O, OCH2CH2O; Q = specified (substituted) (hetero)aryl; Z = O, S], were prepd. Thus, 3-(4-imidazolylmethylidenyl)-4,6-dimethyl-2-indolinone inhibited CDK2 with IC50 = <0.78 μM.

IT 15966-93-5 186611-30-3 186611-31-4
186611-33-6 186611-34-7 186611-37-0
215434-66-5 215536-85-9 215536-87-1
215536-88-2 215536-91-7 215537-01-2
215537-21-6 215537-24-9 215537-55-6
215537-79-4 215543-92-3 215543-93-4
215543-94-5 215543-95-6 215543-96-7
215543-97-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of 3-(hetero)arylmethylidene-2-indolinone derivs. as modulators of protein kinase activity for use in treating cancer)

RN 15966-93-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-30-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 186611-31-4 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)



RN 186611-33-6 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 186611-34-7 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-37-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 215434-66-5 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-1,3-dihydro-4-methyl-3-[(1-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 215536-85-9 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-1,3-dihydro-4-methyl-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 215536-87-1 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 215536-88-2 CAPLUS

L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215536-91-7 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 215537-01-2 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 215537-21-6 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-1,3-dihydro-4-methyl-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)

L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 215543-92-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (CA INDEX NAME)



RN 215543-93-4 CAPLUS
CN 2H-Indol-2-one, 3-[(5-acetyl-3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 215543-94-5 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215543-95-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5,6-dimethoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)

L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 215537-24-9 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 215537-55-6 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 215537-79-4 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)

L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 215543-96-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-[[4-(methoxycarbonyl)benzoyl]amino]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215543-97-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 706 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:685118 CAPLUS
DOCUMENT NUMBER: 129:310905
TITLE: Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
INVENTOR(S): Clary, Douglas
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9845708 | A1 | 19981015 | WO 1998-US6842 | 19980407 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| AU 9868876 | A | 19981030 | AU 1998-68876 | 19980407 |
| US 2002068361 | A1 | 20020606 | US 1998-57150 | 19980407 |
| US 6235769 | B1 | 20010522 | US 1998-109883 | 19980702 |
| PRIORITY APPLN. INFO.: | | | US 1997-43207P P | 19970408 |
| | | | US 1997-51715P P | 19970703 |
| | | | WO 1998-US6842 W | 19980407 |

AB The invention relates to methods of evaluating the specific function of a receptor protein tyrosine kinase in cells by activating the receptor in a ligand-independent fashion. In addition, the invention includes methods of identifying compds. that modulate receptor protein tyrosine kinase function. The invention also relates to a method of preventing or treating an abnormal condition caused by an aberration in the function of the C-RET receptor, and specifically to the treatment and prevention of neurodegenerative disorders by administering a compound that modulates the function of the C-RET receptor.
IT 204003-90-7 204003-91-8 204003-96-3
204003-97-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases, and screening method)

L35 ANSWER 706 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 706 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 204003-90-7 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-91-8 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-96-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[[3,5-bis(1-methylethyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-97-4 CAPLUS
CN 1H-Indole-5-propanoic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

L35 ANSWER 707 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:151222 CAPLUS
DOCUMENT NUMBER: 128:164361
TITLE: Crystal structures of a protein tyrosine kinase
INVENTOR(S): Mohammadi, Moosa; Li, Sun; Liang, Congxin; Schlessinger, Joseph; Hubbard, Stevan R.; McMahon, Gerald; Tang, Peng C.
PATENT ASSIGNEE(S): Sugen, Inc., USA; Mohammadi, Moosa; Li, Sun; Liang, Congxin; Schlessinger, Joseph; Hubbard, Stevan R.; McMahon, Gerald; Tang, Peng C.
SOURCE: PCT Int. Appl., 493 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9807835 | A2 | 19980226 | WO 1997-US14885 | 19970821 |
| WO 9807835 | A3 | 19981001 | | |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| US 5942428 | A | 19990824 | US 1996-701191 | 19960821 |
| CA 2263838 | A1 | 19980226 | CA 1997-2263838 | 19970821 |
| AU 9741603 | A | 19980306 | AU 1997-41603 | 19970821 |
| EP 931152 | A2 | 19990728 | EP 1997-939534 | 19970821 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2001514484 | T | 20010911 | JP 1998-511036 | 19970821 |
| US 6682921 | B1 | 20040127 | US 2000-664526 | 20000918 |
| US 2004185547 | A1 | 20040923 | US 2004-763418 | 20040126 |
| PRIORITY APPLN. INFO.: | | | US 1996-701191 A | 19960821 |
| | | | US 1996-34168P P | 19961219 |
| | | | WO 1997-US14885 W | 19970821 |
| | | | US 1998-188809 B1 | 19981109 |
| | | | US 2000-664526 A3 | 20000918 |

OTHER SOURCE(S): MARPAT 128:164361
AB The present invention relates to the 3-dimensional structures of a protein tyrosine kinase optionally complexed with one or more compds. Thus, a 310-amino acid fragment fibroblast growth factor receptor 1 (residues 456-765, FGFR1) was recombinantly prepared containing the amino acid substitutions Cys488→Ala, Cys584→Ser, and Leu457→Val, and an addnl. 5 residues (Ser-Ala-Ala-Gly-Thr) at the N-terminus. X-ray crystallog. yielded the atomic structural coordinates of crystalline FGFR1 and its complexes with adenylyl diphosphonate, 3-[(3-(2-carboxyethyl)-4-methylpyrrol-5-yl)methylene]-2-indolinone, or 3-[4-(4-formylpiperazine-1-

L35 ANSWER 707 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
yl)benzylidenyl]-2-indolinone. Two forms of cryst. FGFR1 were obtained: one form (designated C2-A form) with unit cell dimensions of a = 208.3, b = 57.2, c = 65.5Å and β = 107.2°, and another C2-B form with dimensions a = 211.6, b = 51.3, c = 66.1Å and β = 107.7°. The overall structure of FGFR1 is bi-lobate. The N-terminal lobe of FGFR1 spans amino acid residues 456-567 and comprises a curled β-sheet of five antiparallel strands and one α-helix. The C-terminal lobe spans amino acid residues 568-765 and comprises two β-strands and seven α-helixes. The at. coordinates that define the structures of the protein tyrosine kinase and any of the compds. bound to it are pertinent to methods for detg. the 3-dimensional structures of protein tyrosine kinases with unknown structure and to methods that identify modulators of protein tyrosine kinase functions.
IT 186611-14-3D, complex with fibroblast growth factor receptor 1
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(crystal structures of a protein tyrosine kinase)
RN 186611-14-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:147306 CAPLUS
DOCUMENT NUMBER: 128:204803
TITLE: Indolinone combinatorial libraries and related products and methods for the treatment of disease
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Hirth, Klaus
Peter; Shawver, Laura Kay; et al.
PATENT ASSIGNEE(S): Sugen, Inc., USA; Tang, Peng Cho; Sun, Li; McMahon, Gerald
SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9807695 | A1 | 19980226 | WO 1997-US14736 | 19970820 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| CN 1155838 | A | 19970730 | CN 1996-190616 | 19960605 |
| CA 2264220 | A1 | 19980226 | CA 1997-2264220 | 19970820 |
| EP 929520 | A1 | 19990721 | EP 1997-939480 | 19970820 |
| EP 929520 | B1 | 20051102 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2001503736 | T | 20010321 | JP 1998-510973 | 19970820 |
| EP 1247803 | A2 | 20021009 | EP 2002-77564 | 19970820 |
| EP 1247803 | A3 | 20021016 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| AT 308520 | T | 20051115 | AT 1997-939480 | 19970820 |
| ES 2251741 | T3 | 20060501 | ES 1997-939480 | 19970820 |
| AU 9741556 | A | 19980306 | AU 1997-41556 | 19970821 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 1996-702232 | A | 19960823 |
| US 1996-31585P | P | 19961205 |
| US 1996-31586P | P | 19961205 |
| US 1996-31588P | P | 19961205 |
| US 1996-32546P | P | 19961205 |
| US 1997-32547P | P | 19961205 |
| US 1997-45565P | P | 19970505 |

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

| | | |
|---|---|---|
| US 1997-45566P | P | 19970505 |
| US 1997-45714P | P | 19970505 |
| US 1997-45715P | P | 19970505 |
| US 1997-46843P | P | 19970505 |
| EP 1997-939480 | A3 | 19970820 |
| WO 1997-US14736 | W | 19970820 |

OTHER SOURCE(S): MARPAT 128:204803
GI




I

AB The invention relates to indolinone derivs. capable of modulating, regulating, and/or inhibiting protein kinase signal transduction. The compds. are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis, and restenosis, and metabolic diseases such as diabetes. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone system, in particular at the 1' position of the indole ring. Indolinone compds. that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano[b]pyrrole moiety. Indolinone compds. that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate protein kinases. This invention also features novel hydrosol. indolinone compds. that are tyrosine kinase inhibitors, and related products and methods. Approx. 1200 title compds., such as I, were prepared by combinatorial condensation of certain (un)substituted indolinones with aldehydes at the 3-position. I gave complete inhibition of MET kinase at chimeric MET receptors in vitro.
IT 91822-51-4P 186611-53-0P 203988-31-2P, 3-[(1-Methylpyrrol-2-yl)methylidenyl]-5,7-dibromo-2-indolinone 203988-38-9P, 3-[(Pyrrol-2-yl)methylidenyl]-5,7-dibromo-2-indolinone 203988-42-5P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203988-47-0P, 3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-iodo-2-indolinone 203988-52-7P, 3-[(Pyrrol-2-yl)methylidenyl]-5-iodo-2-indolinone

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
203988-54-9P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203988-57-2P, 3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203988-62-9P, 3-[(Pyrrol-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203988-64-1P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203988-67-4P, 3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203988-72-1P, 3-[(Pyrrol-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203988-74-3P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203988-77-6P,

3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203988-82-3P, 3-[(Pyrrol-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203988-84-5P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203988-87-8P, 3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203988-92-5P, 3-[(Pyrrol-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203988-94-7P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203988-97-0P, 3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203989-02-0P, 3-[(Pyrrol-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203989-04-2P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203989-05-3P,

3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone 203989-08-6P, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone 203989-14-4P, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone 203989-17-7P, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone 203989-24-6P, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone 203989-27-9P, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone 203989-35-9P, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203989-40-6P, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203989-52-0P, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203989-56-4P, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203989-65-5P, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203989-68-8P, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203989-75-7P, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone 203989-78-0P, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
indolinone 203989-88-2P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203989-98-4P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203990-08-3P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203990-18-5P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203990-28-7P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203990-38-9P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203990-48-1P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone 203991-59-7P, 3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5,7-dibromo-2-indolinone 203991-62-2P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203991-69-9P, 3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-iodo-2-indolinone 203991-72-4P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203991-79-1P, 3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203991-82-6P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203991-89-3P,

3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203991-92-8P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203991-99-5P, 3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203992-02-3P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203992-09-0P
,
3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203992-12-5P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203992-19-2P , 3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203992-22-7P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203993-71-9P, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5,7-dibromo-2-indolinone 203993-80-0P, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-iodo-2-indolinone 203993-89-9P, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone 203993-98-0P,

3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203994-07-4P, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203994-16-5P, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203994-25-6P , 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone 203994-35-8P, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone 203994-53-0P, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone 203994-72-3P, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone 203994-91-6P, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203995-11-3P,

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203995-26-0P, 3-[[2-Chloro-4-(methoxycarbonyl)-3-

[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203995-36-2P, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone 203995-39-5P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone 203995-48-6P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone 203995-57-7P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone 203995-66-8P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203995-75-9P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-

methylpyrrol-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203995-84-0P, 3-[[2-(Ethoxycarbonyl)-4-

(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203995-93-1P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone 203996-03-6P, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203996-13-8P, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203996-23-0P, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203996-33-2P, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203996-43-4P, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203996-53-6P , 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203996-63-8P, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 204003-84-9P 204003-85-0P 204003-88-3P 204003-89-4P 204003-90-7P 204003-91-8P 204003-96-3P 204003-97-4P 204004-29-5P 204004-86-4P 204004-92-2P 204004-94-4P 204005-03-8P 204005-21-0P 204005-38-9P 204005-39-0P 204005-46-9P 204005-54-9P 204005-56-1P 204005-58-3P 204005-59-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and testing of indolinone combinatorial library as protein kinase inhibitors)
RN 91822-51-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 186611-53-0 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 203988-31-2 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-1,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 203988-38-9 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (9CI)
(CA INDEX NAME)



RN 203988-42-5 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203988-47-0 CAPLUS
CN 2H-Indol-2-one,
1,3-dihydro-5-iodo-3-[(1-methyl-1H-pyrrol-2-yl)methylene]-
(9CI) (CA INDEX NAME)



RN 203988-52-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-iodo-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA
INDEX NAME)



RN 203988-54-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)



RN 203988-57-2 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-4-methyl-3-[(1-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203988-62-9 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-4-methyl-3-(1H-pyrrol-2-ylmethylene)-(9CI) (CA INDEX NAME)



RN 203988-64-1 CAPLUS
CN 2H-Indol-2-one,
5-bromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 203988-67-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(1-methyl-1H-pyrrol-2-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 203988-72-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-(1H-pyrrol-2-

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
ylmethylene)- (9CI) (CA INDEX NAME)



RN 203988-74-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203988-77-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203988-82-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203988-84-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203988-87-8 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203988-92-5 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203988-94-7 CAPLUS
CN Morpholine, 4-[[3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203988-97-0 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-1,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 203989-02-0 CAPLUS
CN 2H-Indol-2-one,
5-(2-chloroethyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-(9CI) (CA INDEX NAME)



RN 203989-04-2 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203989-05-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-08-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid,
5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-14-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203989-17-7 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-24-6 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-27-9 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl
ester (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203989-35-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX
NAME)



RN 203989-40-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-52-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203989-56-4 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-65-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX
NAME)



RN 203989-68-8 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203989-75-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-78-0 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl
ester (9CI) (CA INDEX NAME)



RN 203989-88-2 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Indole-5-sulfonamide, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203990-38-9 CAPLUS
CN Morpholine, 4-[[3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203990-48-1 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 203991-59-7 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-1,3-dihydro-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 203991-62-2 CAPLUS
CN 2H-Indol-2-one, [illegible]thyl-1H-pyrrol-2-yl)methylene]-1,3-



L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203989-98-4 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)



RN 203990-08-3 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 203990-18-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203990-28-7 CAPLUS

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
dihydro- (9CI) (CA INDEX NAME)



RN 203991-69-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-iodo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 203991-72-4 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)



RN 203991-79-1 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-4-methyl-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 203991-82-6 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203991-89-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 203991-92-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203991-99-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203992-02-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203993-71-9 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 203993-80-0 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)



RN 203993-89-9 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203992-09-0 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203992-12-5 CAPLUS
CN Morpholine, 4-[[3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203992-19-2 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-1,3-dihydro-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 203992-22-7 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203993-98-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203994-07-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203994-16-5 CAPLUS
CN Morpholine, 4-[[3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203994-25-6 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 203994-35-8 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 203994-53-0 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203994-72-3 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-chloro-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 203994-91-6 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 203995-11-3 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203995-26-0 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 203995-36-2 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 203995-39-5 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203995-48-6 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)



RN 203995-57-7 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)



RN 203995-66-8 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203995-75-9 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)



RN 203995-84-0 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)



RN 203995-93-1 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 203996-33-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203996-43-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203996-53-6 CAPLUS
CN Morpholine, 4-[[3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203996-63-8 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204003-84-9 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(4,5,6,7-tetrahydro-1H-indol-2-

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203996-03-6 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 203996-13-8 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)



RN 203996-23-0 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
yl)methylene]- (9CI) (CA INDEX NAME)



RN 204003-85-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 204003-88-3 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 204003-89-4 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 204003-90-7 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 204003-91-8 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-96-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[[3,5-bis(1-methylethyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-97-4 CAPLUS
CN 1H-Indole-5-propanoic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204004-29-5 CAPLUS

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 204005-03-8 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 204005-21-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1,2,4-trimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 204005-38-9 CAPLUS
CN 2H-Indol-2-one, 5-amino-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-39-0 CAPLUS
CN 2H-Indol-2-one, 5-amino-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 2H-Indol-2-one, 5-amino-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204004-86-4 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(5-amino-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 204004-92-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 204004-94-4 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)



RN 204005-54-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 204005-56-1 CAPLUS
CN 2H-Indol-2-one, 5-amino-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-58-3 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-59-4 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L35 ANSWER 709 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:735056 CAPLUS
DOCUMENT NUMBER: 129:330650
TITLE: Preparation of 3-benzylidene-2-indolinones and analogs
as tyrosine kinase signal transduction modulators
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen Inc., USA
SOURCE: U.S., 34 pp., Cont.-in-part of U.S. Ser. No. 485,323.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 5834504 | A | 19981110 | US 1996-655225 | 19960605 |
| US 5880141 | A | 19990309 | US 1995-485323 | 19950607 |
| JP 10504323 | T | 19980428 | JP 1997-501363 | 19960605 |
| JP 3231044 | B2 | 20011119 | | |
| EP 934931 | A2 | 19990811 | EP 1999-103667 | 19960605 |
| EP 934931 | A3 | 19991020 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI | | | | |
| JP 2000026412 | A | 20000125 | JP 1999-159567 | 19960605 |
| ES 2159741 | T3 | 20011016 | ES 1996-918093 | 19960605 |
| PT 769947 | T | 20011031 | PT 1996-918093 | 19960605 |

PRIORITY APPLN. INFO.: US 1995-485323 A2 19950607
EP 1996-918093 A3 19960605
JP 1997-501363 A3 19960605

OTHER SOURCE(S): MARPAT 129:330650
GI



I

AB Title compds. [I; R1 = H or alkyl; R2 = 2-halo-4-hydroxy- or -alkoxyphenyl, 4-hydroxy- or -alkoxyphenyl, 4-(di)(alkyl)aminophenyl, heteroaryl, etc.; R4-R7 = H, halo, alkyl, alkoxy, etc.; X = O or S] were prepared Thus, oxindole was condensed with 2-chloro-4-methoxybenzaldehyde to give I (R1 = R4-R7 = H, R2 = 2-chloro-4-methoxyphenyl, X = O). Data for biol. activity of I were given.

L35 ANSWER 709 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
IT 15966-93-5P 186610-93-5P 186610-94-6P
186611-14-3P 186611-15-4P 186611-16-5P
186611-29-0P 186611-30-3P 186611-31-4P
186611-35-8P 186611-36-9P 186611-37-0P
186611-38-1P 186611-39-2P 186611-48-3P
204005-03-8P 204005-46-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-benzylidene-2-indolinones and analogs as tyrosine kinase
signal transduction modulators)
RN 15966-93-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186610-93-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186610-94-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-14-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-

L35 ANSWER 709 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 186611-15-4 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-16-5 CAPLUS
CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 186611-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-30-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)

L35 ANSWER 709 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 186611-31-4 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)



RN 186611-35-8 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-36-9 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

L35 ANSWER 709 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-03-8 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 181 THERE ARE 181 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 709 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 186611-37-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-38-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-39-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



L35 ANSWER 710 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:542764 CAPLUS
DOCUMENT NUMBER: 129:175549
TITLE: Preparation of 3-(hetero)arylmethylene-2-indolinones as tyrosine kinase signal transduction modulators
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S., 37 pp., Cont.-in-part of U. S. Ser. No. 485,323.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 5792783 | A | 19980811 | US 1996-655223 | 19960605 |
| US 5880141 | A | 19990309 | US 1995-485323 | 19950607 |
| JP 10504323 | T | 19980428 | JP 1997-501363 | 19960605 |
| JP 3231044 | B2 | 20011119 | | |
| EP 934931 | A2 | 19990811 | EP 1999-103667 | 19960605 |
| EP 934931 | A3 | 19991020 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI | | | | |
| JP 2000026412 | A | 20000125 | JP 1999-159567 | 19960605 |
| ES 2159741 | T3 | 20011016 | ES 1996-918093 | 19960605 |
| PT 769947 | T | 20011031 | PT 1996-918093 | 19960605 |
| US 6316635 | B1 | 20011113 | US 1999-293518 | 19990415 |
| US 6846839 | B1 | 20050125 | US 1999-333703 | 19990616 |
| US 2002102608 | A1 | 20020801 | US 2001-897755 | 20010703 |
| US 6906093 | B2 | 20050614 | | |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 1995-485323 | A2 | 19950607 |
| EP 1996-918093 | A3 | 19960605 |
| JP 1997-501363 | A3 | 19960605 |
| US 1996-655223 | A2 | 19960605 |
| US 1996-655224 | A2 | 19960605 |
| US 1996-655226 | A2 | 19960605 |
| US 1996-655255 | B2 | 19960605 |
| US 1996-659191 | A1 | 19960605 |
| US 1996-702232 | B2 | 19960823 |
| US 1997-915366 | A2 | 19970820 |
| US 1998-82056P | P | 19980416 |
| US 1998-212494 | A2 | 19981215 |

OTHER SOURCE(S): MARPAT 129:175549
GI

L35 ANSWER 710 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

AB Title compds. [I; R1 = H or alkyl; R2 = (un)substituted (hetero)aryl; R4-R7 = H, halo, alkyl, alkoxy, etc.; X = O or S] were prepared Thus, oxindole was condensed with 4-pyridinecarboxaldehyde to give I (R1,R4-R7 = H, R2 = 4-pyridinyl, X = O). Data for biol. activity of I were given.

IT 15966-93-5P 91822-51-4P 186610-93-5P
186610-94-6P 186611-14-3P 186611-15-4P
186611-16-5P 186611-17-6P 186611-29-0P
186611-30-3P 186611-31-4P 186611-35-8P
186611-36-9P 186611-37-0P 186611-38-1P
186611-39-2P 186611-48-3P 186611-56-3P
186611-67-6P 204005-46-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(hetero)arylmethylene-2-indolinones as tyrosine kinase signal transduction modulators)

RN 15966-93-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 91822-51-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (CA INDEX NAME)



RN 186610-93-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186610-94-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-14-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 186611-15-4 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-16-5 CAPLUS
CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 186611-17-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 186611-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-30-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-31-4 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)



RN 186611-35-8 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-36-9 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-37-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-

L35 ANSWER 710 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-38-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-39-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L35 ANSWER 710 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 186611-56-3 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)



RN 186611-67-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-nitro- (9CI) (CA INDEX NAME)



RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 179 THERE ARE 179 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 711 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:429042 CAPLUS
DOCUMENT NUMBER: 129:117426
TITLE: Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases
AUTHOR(S): Sun, Li; Tran, Ngoc; Tang, Flora; App, Harald; Hirth, Peter; McMahon, Gerald; Tang, Cho
CORPORATE SOURCE: SUGEN Inc, Redwood City, CA, 94063, USA
SOURCE: Journal of Medicinal Chemistry (1998), 41(14), 2588-2603
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs). These compds. have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells. By modifying the 3-substituted indolin-2-ones, we have identified compds. which showed selective inhibition of the ligand-dependent autophosphorylation of various RTKs at submicromolar levels in cells. Structure-activity anal. for these compds. and their relative potency and selectivity to inhibit particular RTKs has determined that (1) 3-[(five-membered heteroaryl ring)methylidenyl]indolin-2-ones are highly specific against the VEGF (Flk-1) RTK activity, (2) 3-(substituted benzylidenyl)indolin-2-ones containing bulky group(s) in the Ph ring at the C-3 position of indolin-2-ones showed high selectivity toward the EGF and Her-2 RTKs, and (3) the compound containing an extended side chain at the C-3 position of the indolin-2-one exhibited high potency and selectivity when tested against the PDGF and VEGF (Flk-1) RTKs. Recent published crystallog. data for two of these 3-substituted indolin-2-ones provides a rationale to suggest that these compds. may bind in the ATP binding pocket of RTKs. The structure-activity anal. supports the use of subsets of these compds. as specific chemical leads for the development of RTK-specific drugs with broad application for the treatment of human diseases.

IT 194413-58-6P 210303-07-4P 210303-45-0P
210303-46-1P 210303-47-2P 210303-48-3P
210303-49-4P 210303-50-7P 210303-51-8P
210303-52-9P 210303-53-0P 210303-54-1P
210303-55-2P 210303-56-3P 210303-57-4P
210303-58-5P 210303-59-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and evaluation of 3-substituted indolin-2-ones as inhibitors of selective growth factor receptors)

RN 194413-58-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

L35 ANSWER 711 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Double bond geometry as shown.



RN 210303-07-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-45-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-methyl-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-46-1 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L35 ANSWER 711 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 210303-47-2 CAPLUS
CN 2H-Indol-2-one, 6-fluoro-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-49-4 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-50-7 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L35 ANSWER 711 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 210303-51-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-52-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-6-fluoro-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-53-0 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L35 ANSWER 711 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 210303-54-1 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-55-2 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-56-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]-, (3Z)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-57-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-nitro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

L35 ANSWER 711 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 210303-58-5 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-59-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-methyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L35 ANSWER 712 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:640690 CAPLUS
DOCUMENT NUMBER: 127:314804
TITLE: Assays for KDR/FLK-1 receptor tyrosine kinase inhibitors, and use of the inhibitors for treatment of vasculogenesis- and angiogenesis-related diseases
INVENTOR(S): Hirth, Klaus P.; McMahon, Gerald; Shawver, Laura K.
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9734920 | A1 | 19970925 | WO 1997-US3378 | 19970304 |
| W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| AU 9720667 | A | 19971010 | AU 1997-20667 | 19970304 |
| PRIORITY APPLN. INFO.: | | | US 1996-621734 A | 19960321 |
| | | | WO 1997-US3378 W | 19970304 |

AB Processes are disclosed for the identification of compds. and pharmaceutical compns. capable of selectively and potently inhibiting KDR/FLK-1 tyrosine kinase signal transduction in order to inhibit vasculogenesis and/or angiogenesis. The invention also relates to compds. and compns. identified using the methods of the invention and the use thereof for the treatment of disease relating to inappropriate vasculogenesis and/or angiogenesis. The invention provides an assay cascade comprised of several "filter steps" of increasing selectivity which identify a limited subset of candidate compds. affecting the VEGF receptor on the mol. level.
IT 91822-51-4, SU 4314 204005-46-9, SU 5416
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(KDR/FLK-1 receptor tyrosine kinase inhibitor identification assay, and use of compds. for treatment of vasculogenesis- and angiogenesis-related diseases)
RN 91822-51-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (CA INDEX NAME)

L35 ANSWER 712 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)



L35 ANSWER 713 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:322412 CAPLUS
DOCUMENT NUMBER: 127:44439
TITLE: Structure of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
AUTHOR(S): Mohammadi, Moosa; McMahon, Gerald; Sun, Li; Tang, Cho; Hirth, Peter; Yeh, Brian K.; Hubbard, Stevan R.; Schlessinger, Joseph
CORPORATE SOURCE: Dep. Pharmacology, New York Univ. Med. Center, New York, NY, 10016, USA
SOURCE: Science (Washington, D. C.) (1997), 276(5314), 955-960
CODEN: SCIEAS; ISSN: 0036-8075
PUBLISHER: American Association for the Advancement of Science
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A new class of protein tyrosine kinase inhibitors was identified that is based on an oxindole core (indolinones). Two compds. from this class inhibited the kinase activity of fibroblast growth factor receptor 1 (FGFR1) and showed differential specificity toward others receptor tyrosine kinases. Crystal structures of the tyrosine kinase domain of FGFR1 in complex with the two compds. were determined The oxindole occupies the sites in which the adenine of ATP binds, whereas the moieties that extend from the oxindole contact residues in the hinge region between the two kinase lobes. The more specific inhibitor of FGFR1 induces a conformational change in the nucleotide-binding loop. This structural information will facilitate the design of new inhibitors for use in the treatment of cancer and other diseases in which cell signaling by tyrosine kinases plays a crucial role in disease pathogenesis.
IT 186611-14-3, SU 5402
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibitor; structure of tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors)
RN 186611-14-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:140244 CAPLUS
DOCUMENT NUMBER: 126:139901
TITLE: Indolinone compounds capable of modulating tyrosine kinase signal transduction
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9640116 | A1 | 19961219 | WO 1996-US8903 | 19960605 |
| W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN | | | | |
| RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| US 5880141 | A | 19990309 | US 1995-485323 | 19950607 |
| CA 2192797 | A1 | 19961219 | CA 1996-2192797 | 19960605 |
| CA 2192797 | C | 20060516 | | |
| AU 9660441 | A | 19961230 | AU 1996-60441 | 19960605 |
| AU 706597 | B2 | 19990617 | | |
| EP 769947 | A1 | 19970502 | EP 1996-918093 | 19960605 |
| EP 769947 | B1 | 20010502 | | |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| BR 9606410 | A | 19971230 | BR 1996-6410 | 19960605 |
| JP 10504323 | T | 19980428 | JP 1997-501363 | 19960605 |
| JP 3231044 | B2 | 20011119 | | |
| HU 9701694 | A2 | 19990628 | HU 1997-1694 | 19960605 |
| EP 934931 | A2 | 19990811 | EP 1999-103667 | 19960605 |
| EP 934931 | A3 | 19991020 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI | | | | |
| JP 2000026412 | A | 20000125 | JP 1999-159567 | 19960605 |
| AT 200863 | T | 20010515 | AT 1996-918093 | 19960605 |
| ES 2159741 | T3 | 20011016 | ES 1996-918093 | 19960605 |
| PT 769947 | T | 20011031 | PT 1996-918093 | 19960605 |
| NO 9605377 | A | 19970212 | NO 1996-5377 | 19961213 |
| NO 311355 | B1 | 20011119 | | |
| HK 1001121 | A1 | 20070316 | HK 1998-100009 | 19980102 |
| HK 1011933 | A1 | 20020118 | HK 1998-113193 | 19981211 |
| GR 3036315 | T3 | 20011031 | GR 2001-401166 | 20010731 |
| PRIORITY APPLN. INFO.: | | | US 1995-485323 A | 19950607 |
| | | | EP 1996-918093 A3 | 19960605 |
| | | | JP 1997-501363 A3 | 19960605 |
| | | | WO 1996-US8903 W | 19960605 |

OTHER SOURCE(S): MARPAT 126:139901
AB The present invention relates to organic mols. capable of modulating tyrosine

L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Representatives of the 5 different classes of compds. described are SU 4932 [3-(2-chloro-4-hydroxybenzylidenyl)-2-indolinone], SU 4312 [3-(4-dimethylaminobenzylidenyl)-2-indolinone], SU 5416 [3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone], SU 5204 [3-(2-ethoxybenzylidenyl)-2-indolinone], and SU 4942 [3-(4-bromobenzylidenyl)-2-indolinone]. Diseases which these compds. and their pharmaceutically acceptable prepns. may be effective against include arthritis, hepatic cirrhosis, diabetic nephropathy and psoriasis.

IT 15966-93-5P, SU 5408 91822-51-4P, SU 4314
186610-93-5P, SU 5404 186610-94-6P, SU 5406
186611-14-3P, SU 5402 186611-15-4P, SU 5403
186611-16-5P, SU 5405 186611-17-6P, SU 5407
186611-29-0P, SU 5453 186611-30-3P, SU 5454
186611-31-4P, SU 5455 186611-32-5P, SU 5456
186611-33-6P, SU 5459 186611-34-7P, SU 5460
186611-35-8P, SU 5461 186611-36-9P, SU 5462
186611-37-0P, SU 5463 186611-38-1P, SU 5464
186611-39-2P, SU 5465 186611-48-3P, SU 5477
186611-49-4P, SU 5478 186611-50-7P, SU 5479
186611-53-0P, SU 5612 186611-54-1P, SU 5613
186611-56-3P, SU 5614 186611-65-4P, SU 5624
186611-66-5P, SU 5625 186611-67-6P, SU 5626
204005-46-9P, SU 5416
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolinones capable of modulating tyrosine kinase signal transduction)

RN 15966-93-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 91822-51-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (CA INDEX NAME)

L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 186610-93-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186610-94-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-14-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 186611-15-4 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 186611-16-5 CAPLUS
CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 186611-17-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 186611-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-30-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)

L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 186611-31-4 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)



RN 186611-32-5 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-diiodo-4-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-33-6 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 186611-34-7 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 186611-35-8 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-36-9 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-37-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 186611-38-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-39-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-49-4 CAPLUS
CN 2H-Indol-2-one, 3-[(5-ethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI)

L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(CA INDEX NAME)



RN 186611-50-7 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-4-(1-methylethenyl)-1H-pyrrol-2-yl]methylene)-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-53-0 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-54-1 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-56-3 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)

L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 186611-65-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-nitro-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-66-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-5-nitro- (9CI) (CA INDEX NAME)



RN 186611-67-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-nitro- (9CI) (CA INDEX NAME)



RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)

L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L35 ANSWER 715 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:746204 CAPLUS
DOCUMENT NUMBER: 126:18783
TITLE: Substituted indolylmethylene-oxindole analogs as tyrosine kinase inhibitors
INVENTOR(S): Battistini, Carlo; Ballinari, Dario; Ermoli, Antonella; Penco, Sergio; Vioglio, Sergio
PATENT ASSIGNEE(S): Pharmacia S.P.A., Italy
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9632380 | A1 | 19961017 | WO 1996-EP1165 | 19960314 |
| W: JP, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| EP 764152 | A1 | 19970326 | EP 1996-907500 | 19960314 |
| EP 764152 | B1 | 20020731 | | |
| R: DE, ES, FR, GB, IT, SE | | | | |
| JP 10501821 | T | 19980217 | JP 1996-530667 | 19960314 |
| ES 2181875 | T3 | 20030301 | ES 1996-907500 | 19960314 |
| US 5849710 | A | 19981215 | US 1996-750208 | 19961204 |
| PRIORITY APPLN. INFO.: | | | GB 1995-7298 A | 19950407 |
| | | | WO 1996-EP1165 W | 19960314 |

OTHER SOURCE(S): MARPAT 126:18783
GI



AB Indol-3-ylmethylene-2-oxindole derivs. I and their pharmaceutically acceptable salts are disclosed [wherein 1 or 2 of R, R1, R2, and R3 = X(CH2)mNH2, X(CH2)mNR4R5, X(CH2)mNHR6, NHC(:NH)NH2, NHC(:NH)NR4R5, NHC(:NH)NHR6, N:CHNH2, N:CHNR4R5, N:CHNHR6, X(CH2)mCOR7, CORa, COR8,

L35 ANSWER 715 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

YCOY'R9, NHR6, NHR10 group; remaining groups within R and R1-R3 = H, halo, amino, OH, alkyl, alkoxy, CO2H, alkoxycarbonyl, alkanoyloxy, cyano, NR4R5; X = O, S, NH; m = 1-4; 1 of R4 and R5 = H or alkyl, and other = alkyl; or NR4R5 forms satd. monoheterocycle; R6 = alkanoyl, 1- to 3-residue (un)substituted peptidyl; R7 = OH, amino, alkoxy, NR4R5; Ra = amino terminus of 1- to 3-unit peptidyl; R8 = alkoxy, phenylalkoxy, (CH2)nNH2, (CH2)nNR4R5, (CH2)nNHR6; n = 1-2; Y, Y' = NH, O; R9 = Ph, alkyl, phenylalkyl; R10 = mono-, di- or trihydroxyalkyl]. I have tyrosine kinase inhibiting activity, and are useful as antiproliferative, antimetastatic, anticancer, antiatheromatous, anti-Alzheimer, and immunomodulating agents.

For example, 2-indolinone reacted with BrCH2COBr and AlCl3 to give the 5-(2-bromoacetyl) deriv., which underwent amination with piperidine and then condensation with indole-3-carboxaldehyde, to give title compd. II (FCE 28484). In tests for inhibition of p45 v-abl kinase and K562 leukemia cells in vitro, II had IC50 of 0.78 and 4.82 μM, resp.

IT 184020-79-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (indolylmethylene)oxindole analogs as tyrosine kinase inhibitors)
RN 184020-79-9 CAPLUS
CN Methanimidamide, N'-[2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1H-indol-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



L35 ANSWER 716 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1992:490138 CAPLUS
DOCUMENT NUMBER: 117:90138
TITLE: Preparation of 3-(arylmethylene)oxindoles and analogs as gastrin releasing peptide antagonists
INVENTOR(S): Nakanishi, Susumu
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9207830 | A2 | 19920514 | WO 1991-US4978 | 19910718 |
| WO 9207830 | A3 | 19920625 | | |
| W: CA, FI, JP, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE | | | | |
| PRIORITY APPLN. INFO.: | | | US 1990-605220 A2 | 19901029 |

OTHER SOURCE(S): MARPAT 117:90138
GI



AB Title compds. [I; RR2 = arylmethylene, NHCONHCO; R1 = Me, Et, (halo)benzyl; R3 = alkyl, halo, groups cited for R4; R4 = H, 5- or 6-O(CH2)nOH, -O(CH2)nCO2H, -OCH2CH(OH)CH2OH, -OCH2Ph, etc.; n = 0-4] were prepared as gastrin releasing peptide antagonists (no data). Thus, 4-(MeO)C6H4NH2 was condensed with ClCH2COCl and the product cyclized to give 5-hydroxyoxindole which was condensed with 3,5-bis(tert-butyl)-4-hydroxybenzaldehyde and the product O-alkylated with 2-(MeO2C)C6H4CH2Br to give, after saponification, title compound II.

IT 142642-28-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as gastrin releasing peptide antagonist)
RN 142642-28-2 CAPLUS
CN Benzoic acid, 2-[[[1-ethyl-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-5-yl]oxy]methyl]- (9CI) (CA INDEX NAME)

L35 ANSWER 716 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L35 ANSWER 717 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1986:478828 CAPLUS
DOCUMENT NUMBER: 105:78828
TITLE: (Aminohydroxypropxy)oxindole derivatives
INVENTOR(S): Michel, Helmut; Kampe, Wolfgang; Strein, Klaus; Bartsch, Wolfgang
PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 36 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| DE 3426419 | A1 | 19860123 | DE 1984-3426419 | 19840718 |
| EP 170117 | A1 | 19860205 | EP 1985-108579 | 19850710 |
| EP 170117 | B1 | 19910130 | | |
| R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE | | | | |
| AT 60582 | T | 19910215 | AT 1985-108579 | 19850710 |
| JP 61036259 | A | 19860220 | JP 1985-156191 | 19850717 |
| US 4826847 | A | 19890502 | US 1986-948422 | 19861230 |

PRIORITY APPLN. INFO.: DE 1984-3426419 A 19840718
EP 1985-108579 A 19850710
US 1985-755497 A1 19850716

OTHER SOURCE(S): CASREACT 105:78828; MARPAT 105:78828
GI



I



II

AB Oxindoles I [R1 = C2-10 nitratoalkyl; X = H, C1-6 allyl; Y = H, C1-6 alkyl; CR2R3R4; R2 = H; R2X = bond; R3 = H, C1-6 alkyl; R4 = C1-6 alkyl, cycloalkyl, (un)substituted aryl or heteroaryl; XY complete a C3-7 cycloalkyl ring], having nitrate-like and β-blocking activity and thus useful in treating heart and circulation disorders (no data), were prepared by 5 methods. 4-(2,3-Epoxypropoxy)indolinone in MeOH was treated

L35 ANSWER 717 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

with O3NCH2CH2CHMeNH2 3 h at room temp. to give 42% II, isolated as the benzoate.

IT 103552-24-5P 103552-25-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as β-blocker)

RN 103552-24-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-[2-hydroxy-3-[[1-methyl-3-(nitrooxy)propyl]amino]propoxy]-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 103552-25-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-[2-hydroxy-3-[[1-methyl-3-(nitrooxy)propyl]amino]propoxy]-3-(1H-pyrrol-2-ylmethylene)-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 103552-24-5
CMF C20 H24 N4 O6



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 103552-26-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with methylnitratopropylamine)

RN 103552-26-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(oxiranylmethoxy)-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)

L35 ANSWER 717 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L35 ANSWER 718 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1985:131907 CAPLUS
DOCUMENT NUMBER: 102:131907
TITLE: 2-Indolinone derivatives, pharmaceuticals containing them, and their intermediate products
INVENTOR(S): Michel, Helmut; Marzenell, Klaus; Kampe, Wolfgang; Bartsch, Wolfgang; Schaumann, Wolfgang
PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H. , Fed. Rep. Ger.
SOURCE: Ger. Offen., 35 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| DE 3310891 | A1 | 19840927 | DE 1983-3310891 | | 19830325 |
| EP 121176 | A1 | 19841010 | EP 1984-103045 | | 19840320 |
| EP 121176 | B1 | 19870930 | | | |
| R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE | | | | | |
| AT 30021 | T | 19871015 | AT 1984-103045 | | 19840320 |
| JP 59176253 | A | 19841005 | JP 1984-54612 | | 19840323 |
| US 4642309 | A | 19870210 | US 1985-780704 | | 19850926 |
| PRIORITY APPLN. INFO.: | | | DE 1983-3310891 | A | 19830325 |
| | | | EP 1984-103045 | A | 19840320 |
| | | | US 1984-592616 | A1 | 19840323 |

OTHER SOURCE(S): CASREACT 102:131907; MARPAT 102:131907
GI



I

AB Indolinones I [R = alkyl, (un)substituted Ph; R1 = R2 = H, R1R2 = bond; R3 = (un)substituted Ph, heterocyclyl; Z = alkylene, O, S, bond] were prepared as antihypertensives and β-sympatholytics (no data). Thus, Et 2-(2-oxiranylmethyl)-6-nitrobenzeneacetate was treated Me2CHNH2 and cyclized by hydrogenation over Pd-C to give 89% 4-[2-hydroxy-3-(isopropylamino)propoxy]-2-indolinone. The latter was condensed with 2-HOC6H4CHO to give 47% I (R = Me2CH, R1R2 = Z = bond, R3 = 2-HOC6H4), which was hydrogenated over Pd-C to give 34% I.BzOH (R = Me2CH, R1 = R2 = H, R3 = 2-HOC6H4, Z = bond).
IT 94533-08-1P 94533-25-2P 94533-28-5P

L35 ANSWER 718 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 94533-08-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 94533-25-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-[2-hydroxy-3-[[2-(4-hydroxyphenoxy)ethyl]amino]propoxy]-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)

PAGE 1-A



L35 ANSWER 718 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 94533-28-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-[2-hydroxy-3-[(2-phenoxyethyl)amino]propoxy]-3-(1H-indol-2-ylmethylene)- (9CI) (CA INDEX NAME)



L35 ANSWER 719 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1969:403203 CAPLUS
DOCUMENT NUMBER: 71:3203
TITLE: Indole chemistry. VI. α,β'-Diindolylmethanes and α,β'-diindolylmethenes
AUTHOR(S): Von Dobeneck, Henning; Wolkenstein, Dieter; Blankenstein, Guenter
CORPORATE SOURCE: Tech. Hochsch. Muenchen, Munich, Fed. Rep. Ger.
SOURCE: Chemische Berichte (1969), 102(4), 1347-56
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
GI For diagram(s), see printed CA Issue.
AB Urorosein was prepared by polycondensation of indol-3-ylglycolic acid, followed by oxidation with the formation of the α,β'-diindolylmethene chromophore. α,β'-Diindolylmethanes (I) were prepared by the reaction of α- and β-unsubstituted indoles with glyoxylic acid; α,β'-diindolylmethenes, from α-formylindoles and β-unsubstituted indoles. Oxo-β,β'- and oxo-α,β'-diindolylmethenes were prepared from β-and α-formylindoles and oxindoles.
IT 22813-86-1P 22813-87-2P 22813-88-3P 22813-89-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 22813-86-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 22813-87-2 CAPLUS
CN 2-Indolinone, 3-(indol-2-ylmethylene)-1-methyl- (8CI) (CA INDEX NAME)



RN 22813-88-3 CAPLUS
CN 2-Indolinone, 3-[(1,3-dimethylindol-2-yl)methylene]- (8CI) (CA INDEX NAME)

L35 ANSWER 719 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 22813-89-4 CAPLUS
CN 2-Indolinone, 3-[(1,3-dimethylindol-2-yl)methylene]-1-methyl- (8CI) (CA INDEX NAME)



L35 ANSWER 720 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1968:496372 CAPLUS
DOCUMENT NUMBER: 69:96372
TITLE: Stokvis reactions. XVII. Vilsmeier reactions with pyrrole and pyrrolone derivatives
AUTHOR(S): Schnierle, Franz; Reinhard, Horst; Dieter, Norbert; Lippacher, Eberhard; Von Dobeneck, Henning
CORPORATE SOURCE: Tech. Hochsch. Muenchen, Munich, Fed. Rep. Ger.
SOURCE: Justus Liebigs Annalen der Chemie (1968), 715, 90-7
CODEN: JLACBF; ISSN: 0075-4617
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 69:96372
AB Vilsmeier formylation of 4-methyl-3-acetyl-2-methoxycarbonylpyrrole gave 4-methyl-2-methoxycarbonyl-3-(1-chloro-3-dimethylimmonio-1-propenyl)pyrrole perchlorate. Formylation of I (R = Me or Et) in the presence of POX3 (X = Br or Cl) gave II. 3-methyl-4-(R-substituted) 3-pyrrolin-2-one, treated as above, gave 3-methyl-4-(R-substituted)-5-(X-substituted)-2-formylpyrrole. The Vilsmeier reactions of 4-methyl-3-(R-substituted)-3-pyrrolin-2-one with ClCOCOCl gave III. 16 references.
IT 19713-94-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 19713-94-1 CAPLUS
CN 2-Indolinone, 3-[(5-chloro-3,4-dimethylpyrrol-2-yl)methylene]- (8CI) (CA INDEX NAME)



L35 ANSWER 721 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1967:433817 CAPLUS
DOCUMENT NUMBER: 67:33817
TITLE: Isoindigo dyes of the pyrrole series
AUTHOR(S): Treibs, Alfred; Jacob, Karl; Dietl, Anton
CORPORATE SOURCE: Tech. Hochsch. Munich, Munich, Fed. Rep. Ger.
SOURCE: Justus Liebigs Ann. Chem. (1967), 702, 112-30
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 67:33817
GI For diagram(s), see printed CA Issue.
AB The dye obtained by lactam ring closure of PhCOCH2CH2CO2H (I) has the structure (II) of a phenylpyrrole-isoindigo (P-II) proposed by Kugel, and is identical with the compound obtained from the O analog, the Pechmann dye
III. In addition to P-II, 4-(3-carboxy-1-phenylpropylidene)-2-phenyl-2-pyrrolin-5-one is formed by condensation of 2-phenyl-2-pyrrolin-5-one with
I, which can also be converted into P-II via a readily proceeding retrocrotonization-retroaldol reaction. New methods for the synthesis of pyrrole-indole-isoindigo derivs. (e.g. IV, X = O, NH, and NMe) are described. The pyrrolylpyrrolinones V (R = CO2Et) (VI) and V (R = H) (VII) and the pyrrolylpyrrole-isoindigo derivs. VIII (R = CO2Et) (IX) and
VIII (R = H) (X) prepared from VI and VII were obtained; IX and X are derivs. of an α, β, α-linked tetrapyrrole.
IT 15966-93-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 15966-93-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



L35 ANSWER 722 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1964:469030 CAPLUS
DOCUMENT NUMBER: 61:69030
ORIGINAL REFERENCE NO.: 61:11958b-c
TITLE: Dinitrocarbazoles
AUTHOR(S): Grotta, Henry M.; Riggle, Charles J.; Bearse, Arthur E.
CORPORATE SOURCE: Battelle Mem. Inst., Columbus, OH
SOURCE: Journal of Organic Chemistry (1964), 29(8), 2474-6
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 61:69030
GI For diagram(s), see printed CA Issue.
AB Nitration of carbazole (I) in AcOH at 75° with 3 equivs. 70% HNO3 gave 3,6-dinitrocarbazole (II). II was reduced and converted by the Sandmeyer reaction to the 3,6-dichlorocarbazole. The alc.-alkali-insol. material from II afforded 1,6-dinitrocarbazole (III). III was converted to the unknown 1,6-dichlorocarbazole (IV). IV was also synthesized from 2,5-dichloronitrobenzene and 2-chloro-aniline. Nitration with NaNO2 and 2
equivs. HNO3 gave a similar ratio of II and III.
IT 91822-51-4P, 2-Indolinone, 3-(pyrrol-2-ylmethylene)-
92148-69-1P, 2-Indolinone, 1-methyl-3-(pyrrol-2-ylmethylene)-
RL: PREP (Preparation)
(preparation of)
RN 91822-51-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (CA INDEX NAME)



RN 92148-69-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-methyl-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



L35 ANSWER 723 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1964:469029 CAPLUS
DOCUMENT NUMBER: 61:69029
ORIGINAL REFERENCE NO.: 61:11957h,11958a-b
TITLE: Reduction of some oxindolylidene derivatives to 3-substituted oxindoles by sodium borohydride
AUTHOR(S): Elliott, I. W.; Rivers, P.
CORPORATE SOURCE: Fisk Univ., Nashville, TN
SOURCE: Journal of Organic Chemistry (1964), 29(8), 2438-40
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB 3α-Picolylidenoxindole (I) was prepared by condensation of 2-pyridinecarboxaldehyde with oxindole in the presence of piperidine. Oxindole and 2-pyridinecarboxaldehyde condensed in MeOH gave 3-oxindolyl-2-pyridylcarbinol. I treated with NaBH4 gave 3α-picolyloxindole. Similar reduction of 3-benzylideneoxindole (II) with NaBH4 gave 3-benzyloxindole (III). III was also obtained from II by treatment with Na dithionite. Oxindole treated with cyclohexanone and piperidine gave cyclohexylidenoxindole (IV). IV hydrogenated over 10% Pd-C gave 3-cyclohexyloxindole (V).. Reduction of IV with NaBH4 also gave V.
Reduction of isoindigo with NaBH4 gave leucoisoindigo.

IT 91822-51-4P, 2-Indolinone, 3-(pyrrol-2-ylmethylene)-
92148-69-1P, 2-Indolinone, 1-methyl-3-(pyrrol-2-ylmethylene)-
RL: PREP (Preparation)
(preparation of)

RN 91822-51-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (CA INDEX NAME)



RN 92148-69-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-methyl-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



=> log h

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 123.95 | 521.23 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -17.94 | -19.45 |

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:06:22 ON 25 MAY 2007